5 Key Takeaways

• 1

  Imagenomix aims to enhance access to precision medicine using an AI-powered platform that analyzes standard H&E slides for molecular signals.

• 2

  In the US, 25% of oncology cases exhaust biopsy tissue before molecular characterization, leading to missed opportunities for mutation testing.

• 3

  AI prescreening can significantly reduce costs and time to treatment by identifying high-probability mutations before expensive confirmatory tests.

• 4

  The Imagenomix platform can improve clinical trial efficiency by screening candidates and preserving tissue for molecular testing.

• 5

  Preliminary studies indicate that Imagenomix's assays for lung and breast cancer mutations are on track for launch in late 2026.